Sabra Healthcare REIT (NASDAQ: SBRA)‘s stock had its “buy” rating restated by research analysts at RBC Capital in a report released on Wednesday, Stock Ratings Network.com reports. They currently have a $33.00 price objective on the stock. RBC Capital’s price target would suggest a potential upside of 18.83% from the stock’s previous close.
Sabra Healthcare REIT (NASDAQ: SBRA) traded up 0.62% on Wednesday, hitting $27.77. Sabra Healthcare REIT has a 52-week low of $17.26 and a 52-week high of $32.40. The stock’s 50-day moving average is currently $26.55. The company has a market cap of $1.037 billion and a price-to-earnings ratio of 42.40.
Sabra Healthcare REIT (NASDAQ: SBRA) last announced its earnings results on Thursday, May 2nd. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.45 by $0.02. The company had revenue of $32.02 million for the quarter, compared to the consensus estimate of $30.71 million. Analysts expect that Sabra Healthcare REIT will post $1.72 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on SBRA. Analysts at Stifel Nicolaus cut their price target on shares of Sabra Healthcare REIT from $34.00 to $32.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Raymond James initiated coverage on shares of Sabra Healthcare REIT in a research note to investors on Friday, July 12th. They set an “outperform” rating and a GBX 28 ($0.42) price target on the stock.
Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Sabra Healthcare REIT currently has a consensus rating of “Buy” and an average price target of $31.25.
Sabra Health Care REIT, Inc (NASDAQ: SBRA) as a wholly owned subsidiary of Sun Healthcare Group, Inc, a provider of nursing, rehabilitative and related specialty healthcare services to the senior population in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.